Oncology

Low-grade inflammation from sleep disturbance may increase risk of dementia and cancer.

Top articles of the week from The American Journal of Pharmacy Benefits.

Targeting KRAS mutations may lead to effective new pancreatic cancer treatments.

A next generation sequencing test to detect lung cancer mutation was also approved.

Non-small cell lung cancer vaccine harnesses peptides to increase immune response.

Dabrafenib and trametinib approved for patients with metastatic non-small cell lung cancer with BRAF V600E mutation.

Novel vaccine improves overall survival in non-small cell lung cancer.

Subcutaneous administration of Rituxan Hycela shortens treatment length to only 5 to 7 minutes.

Rituximab and hyaluronidase human approved for the treatment of adults with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.

The cost of squamous cell cancer of the head and neck is driven primarily by the end-of-life phase. Treatment costs increased following the approval of cetuximab.

When making coverage decisions in oncology, payers find difficulties in translating evidence on treatment effect heterogeneity into coverage policies.

Could household pets be the key to treating breast carcinoma?

Restoring a tumor suppressing gene offers a promising therapeutic target for diffuse intrinsic pontine glioma.

Glucose-starved immune cells elicit stronger response to cancer cells.

Onions contain one of the highest concentrations of quercetin, a flavonoid extract with anti-proliferative effects.

Breast Cancer Survivors Foundation settled to pay $350,000 to legitimate breast cancer charities.

Overutilization of care can produce disparities between high- and low-income counties.

Compounds found in turmeric, red grapes, and apple peels block cancer cells from accessing nutrients need to grow and survive.

Publicly-funded cancer clinical trials are high impact and low cost, experts say.

Adcetris achieves superior outcomes in the treatment of CTCL.

Alectinib found to reduce the risk of disease progression or death by more than 50% in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer.

CAR T-cell therapy shows significant progress towards a cure for multiple myeloma.

New findings show that becoming pregnant after breast cancer does not increase the risk of disease recurrence.

Alecensa is a kinase inhibitor for the treatment of ALK-positive, metastatic non-small cell lung cancer.

Advances in treatment and care improved the 5-year survival rate after diagnosis by 26%.

Cancer treatment also reduced the rates of severe bone complications by more than half.

Pertuzumab-based regimen found to reduce the risk of invasive breast cancer recurrence by 19%.

Analogs of epothilones were even effective against a drug-resistant cancer cell line.

Genomic approach increases understanding of cancer.

Compound in olive oil inhibits disease activity of certain proteins.